Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in Merkel cell carcinoma (MCC)

Published:2017-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Topalian Suzanne L.,Bhatia Shailender,Hollebecque Antoine,Awada Ahmad,Boer Jan Paul De,Kudchadkar Ragini R.,Goncalves Anthony,Delord Jean-Pierre,Martens Uwe M.,Picazo Jose Maria Lopez,Oaknin Ana,Spanos William C.,Aljumaily Raid,Sharfman William H.,Rao Shangbang,Soumaoro Ibrahima,Cao Alexander,Nghiem Paul,Schadendorf Dirk

Publisher

American Association for Cancer Research

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Merkel-cell carcinoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up;ESMO Open;2024-05

2. First-line Immunotherapy for Metastatic Merkel Cell Carcinoma;American Journal of Clinical Oncology;2024-04-08

3. Should Ipilimumab Be the New “Standard” for Refractory MCC?;Journal of Cutaneous Oncology;2024

4. Moderne Diagnostik und Therapie des Merkelzellkarzinoms;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-12

5. Modern diagnostics and treatment of Merkel cell carcinoma;JDDG: Journal der Deutschen Dermatologischen Gesellschaft;2023-10-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP